Literature DB >> 3111573

Bacterial antibiotic resistance before and after clinical application in the United States.

A L Barry, R N Jones.   

Abstract

Mesh：

Substances：

Year:  1987        PMID： 3111573      PMCID： PMC1629239     

Source DB:  PubMed          Journal:  Bull N Y Acad Med        ISSN： 0028-7091


× No keyword cloud information.
  21 in total

1.  Piperacillin and carbenicillin; a collaborative in vitro comparison against 10,838 clinical bacterial isolates.

Authors:  R N Jones; P C Fuchs; E H Gerlach; T L Gavan
Journal:  Cleve Clin Q       Date:  1979

2.  Susceptibility of Enterobacter to cefamandole: evidence for a high mutation rate to resistance.

Authors:  C M Findell; J C Sherris
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

3.  Activity of temocillin and ticarcillin against consecutively isolated Enterobacteriaceae in four medical centres.

Authors:  A L Barry; R N Jones; L W Ayers; T L Gavan; E H Gerlach
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

4.  Fortimicin A: collaborative in vitro susceptibility. Comparison with amikacin and gentamicin against 11,840 clinical bacterial isolates.

Authors:  R N Jones; A L Barry; P C Fuchs; T L Gavan; H M Sommers; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

5.  Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing.

Authors:  P C Fuchs; A L Barry; C Thornsberry; R N Jones; T L Gavan; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

6.  Imipenem (N-formimidoyl thienamycin): in vitro antimicrobial activity and beta-lactamase stability.

Authors:  A L Barry; R N Jones; C Thornsberry; L W Ayers; R Kundargi
Journal:  Diagn Microbiol Infect Dis       Date:  1985-03       Impact factor: 2.803

7.  Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin.

Authors:  R N Jones; P C Fuchs; A L Barry; T L Gavan; H M Sommers; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

8.  Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.

Authors:  R N Jones; P C Fuchs; H M Sommers; T L Gavan; A L Barry; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

9.  Cefpiramide: comparative in-vitro activity and beta-lactamase stability.

Authors:  A L Barry; R N Jones; C Thornsberry; P C Fuchs; L W Ayers; T L Gavan; E H Gerlach; H M Sommers
Journal:  J Antimicrob Chemother       Date:  1985-09       Impact factor: 5.790

10.  Ticarcillin: a collaborative in vitro comparison with carbenicillin against over 9,000 clinical bacterial isolates.

Authors:  P C Fuchs; T L Gavan; E H Gerlach; R N Jones; A L Barry; C Thornsberry
Journal:  Am J Med Sci       Date:  1977 Nov-Dec       Impact factor: 2.378
View more
  5 in total

1.  Multicenter in vitro evaluation of SM-7338, a new carbapenem.

Authors:  R N Jones; K E Aldridge; S D Allen; A L Barry; P C Fuchs; E H Gerlach; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

2.  In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters.

Authors:  R J Fass; W W Gregory; R F D'Amato; J M Matsen; D N Wright; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 3.  Is antimicrobial resistance in hospital microorganisms related to antibiotic use?

Authors:  J E McGowan
Journal:  Bull N Y Acad Med       Date:  1987-04

Review 4.  Pharmacokinetic considerations in the treatment of bacterial keratitis.

Authors:  M C Callegan; R J O'Callaghan; J M Hill
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

5.  Cefotaxime single-dose surgical prophylaxis in a prepaid group practice. Comparisons with other cephalosporins and ticarcillin/clavulanic acid.

Authors:  R N Jones; J M Slepack; W V Wojeski
Journal:  Drugs       Date:  1988       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.